American Association for Cancer Research
00085472can181198-sup-200421_2_supp_5213298_pjhzzl.pdf (71.11 kB)

Supplementary Data from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma

Download (71.11 kB)
journal contribution
posted on 2023-03-31, 02:43 authored by Hiroyuki Yoda, Takahiro Inoue, Yoshinao Shinozaki, Jason Lin, Takayoshi Watanabe, Nobuko Koshikawa, Atsushi Takatori, Hiroki Nagase

Table S1. IC50 values of MYCN-A3-treated 27 cancer cell lines. Table S2. List of Kyoto Encyclopedia Genes and Genome (KEGG) pathways and their relative group-wise expression differences between MYCN-A3 and MYCNcr-a.


Japan Agency for Medical Research and Development


Takeda Science Foundation

Princess Takamatsu Cancer Research Fund





Amplification of MYCN plays a pivotal role in multiple types of tumors and correlates with poor prognosis in high-risk neuroblastoma. Despite recent advances in the treatment of neuroblastoma, no approaches directly target the master oncogene MYCN. Difficulties in targeting the MYCN protein inspired us to develop a new gene-level–inhibitory strategy using a sequence-specific gene regulator. Here, we generated a MYCN-targeting pyrrole-imidazole (PI) polyamide, MYCN-A3, which directly binds to and alkylates DNA at homing motifs within the MYCN transcript. Pharmacologic suppression of MYCN inhibited the proliferation of cancer cells harboring MYCN amplification compared with MYCN nonamplified cancer cells. In neuroblastoma xenograft mouse models, MYCN-A3 specifically downregulated MYCN expression and suppressed tumor progression with no detectable adverse effects and resulted in prolonged overall survival. Moreover, treatment with MYCN-A3, but not MYCN nontargeting PI polyamide, precipitated a copy number reduction of MYCN in neuroblastoma cells with MYCN amplification. These findings suggest that directly targeting MYCN with MYCN-A3 is a novel therapeutic approach to reduce copy number of the MYCN gene for MYCN-amplified neuroblastoma. This study presents a novel approach to drugging an amplified oncogene by showing that targeting gene amplification of MYCN suppresses MYCN expression and neuroblastoma growth.